ANI Pharmaceuticals’ (ANIP) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a research note issued to investors on Monday morning,Benzinga reports. They currently have a $94.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also weighed in on the stock. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Raymond James increased their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. StockNews.com downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, Piper Sandler initiated coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Trading Down 1.9 %

ANIP stock opened at $59.83 on Monday. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market cap of $1.26 billion, a P/E ratio of -108.78 and a beta of 0.71. The company’s 50-day simple moving average is $58.51 and its 200-day simple moving average is $61.42.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.05 earnings per share. As a group, equities analysts forecast that ANI Pharmaceuticals will post 3.5 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Texas Permanent School Fund Corp lifted its holdings in shares of ANI Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after purchasing an additional 172 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in ANI Pharmaceuticals by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after buying an additional 200 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock valued at $299,000 after acquiring an additional 211 shares during the period. Simplicity Wealth LLC grew its position in shares of ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after acquiring an additional 227 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 1.5% in the 1st quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after acquiring an additional 233 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.